MedicalResearch.com Interview with:
Tobias Skillbäck, MD
Clinical Neurochemistry Laboratory
Institute of Neuroscience and Physiology
Department of Neurochemistry, Sahlgrenska Academy
University of Gothenburg Mölndal, Sweden
MedicalResearch.com: What are the main findings of the study?
Dr. Skillbäck: There were two main findings in this study.
First; Levels of t-tau and the T-tau/P-tau ratio in CSF of CJD (Creutzfeldt-Jakob Disease) patients are markedly increased, as compared to patients with Alzheimer’s disease and other dementias, and they are high enough to distinguish CJD against these important differential diagnoses.
Secondly, levels of these biomarkers tend to increase rapidly with disease progress in Creutzfeldt-Jakob Disease. This trend could not be observed for Alzheimer’s disease and other dementias, and could also be used to clinically distinguish CJD and indicates that repeated CSF measurements might be of value if a clinical suspicion of Creutzfeldt-Jakob Diseaseis present.